Abstract:Using multiple databases, we performed gene expression analysis, prognostic analysis, variant analysis, immune analysis, and methylation analysis of the NSD family and identified that NSD3 was highly expressed in pancreatic cancer and associated with poor prognosis, which was validated in our pancreatic cancer cohort. Furthermore, we explored the function and mechanism of NSD3 in pancreatic cancer by in vitro cell experiments. We found that NSD3 may promote the progression of pancreatic cancer by promoting H3K36m2 formation and regulating proliferation‐related gene expression. Background Members of the nuclear receptor‐binding SET domain (NSD) family of histone H3 lysine 36 methyltransferases comprise NSD1, NSD2 (MMSET/WHSC1), and NSD3 (Wolf–Hirschhorn syndrome candidate 1‐like 1, WHSC1L1). While the expression of NSD genes is essential to normal biological processes and cancer, knowledge of their expression levels to prognosticate in cancer remains unclear. Methods We analyzed the expression patterns for NSD family genes across multiple cancer types and examined their association with clinical features and patient survival profiles. Next, we explored the association between NSD3 expression and described features of the tumor microenvironment (TME) in PAAD, a severe type of pancreatic cancer. In particular, we correlated promoter methylation levels for NSD3 with patient outcomes in PAAD. Finally, we explored the putative oncogenic roles for NSD3 using a series of experiments with pancreatic cancer cells. Results We report that the expression of NSD family members is correlated with clinical prognosis across multiple types of cancers. Also, we demonstrate that NSD3 variants are most prevalent among NSD genes across cancers we analyzed. Notably, when compared with NSD1 and NSD2, we find that NSD3 is prominently expressed, and its expression is significantly linked with clinical outcome in pancreatic cancer. Furthermore, NSD3 is frequently amplified, exhibits low promoter methylation, and is correlated with immune cell infiltration and enhanced proliferation of pancreatic cancer. Finally, we demonstrate that knockdown of NSD3 alters H3K36me2 methylation, downstream gene expression and EGFR/ERK signaling in pancreatic cancer cells. Conclusions We find that expression levels, the presence of genetic variants of NSD family genes, as well as their promoter methylation are correlated with clinical outcomes in cancer, including pancreatic cancer. Our in vitro experiments suggest that NSD3 may be relevant to gene expression regulation and growth factor signaling in pancreatic cancer.

Prospect of targeting lysine methyltransferase NSD3 for tumor therapy

NSD3: Advances in cancer therapeutic potential and inhibitors research

Abstract 1397: the Regulation of DNMT3B Expression by Lncrna-Ncrms in Cancer

A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells

NSD Family Proteins: Rising Stars As Therapeutic Targets

Unraveling Methyltransferase-Dependent and Isoform-Specific Functions

Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs

Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases

NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein

Pharmacological Targeting of TNS3 with Histone Deacetylase Inhibitor As a Therapeutic Strategy in Esophageal Squamous Cell Carcinoma.

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

NSD3, a member of nuclear receptor‐binding SET domain family, is a potential prognostic biomarker for pancreatic cancer

KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors

Targeting the Tumor Epigenetic Regulator SETDB1 for Tumor Therapy

Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway

Abstract 4517: Novel chemical degraders targeting NSD2 in head and neck squamous cell carcinoma (HNSCC)

Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2

NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis

Target validation and structure-based virtual screening to Discover potential lead molecules against the oncogenic NSD1 histone methyltransferase

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy